We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
BENEDO (Sun Pharma ANZ Pty Ltd)
Product name
BENEDO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
188 (255 working days)
Active ingredients
Liraglutide
Registration type
NCE/ NBE
Indication
LIRAGLUTIDE RBX / LIRAGLUTIDE SUN / BENEDO is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of
- ≥30 kg/m2 (obese) or
- ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea.
Treatment with LIRAGLUTIDE RBX / LIRAGLUTIDE SUN / BENEDO should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.